Benjamin Garmezy, MD

Benjamin Garmezy, MD, discusses the rationale for developing zelenectide pevedotin in metastatic urothelial carcinoma.

Meta: Benjamin Garmezy, MD discusses future therapeutic prospects for patients with variant renal cell carcinoma (RCC)

Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.

Chandler H. Park, MD, highlights cabozantinib monotherapy data from the SWOG 1500 study in non–clear cell renal cell carcinoma.

Benjamin Garmezy, MD, discusses key factors influencing treatment selection for patients with variant renal cell carcinoma.

The expert panel gives an overview of non–clear cell renal cell carcinoma, highlighting disease subtypes and treatment approaches.

Following a review of research on belzutifan in the advanced RCC space, the expert panel has a comprehensive discussion on treatment approaches and toxicity management.

Focusing on belzutifan, Laurence Albigès, MD, PhD, reviews data from the LITESPARK-005 clinical trial, and Martin H. Voss, MD, discusses the ongoing LITESPARK-011 trial.

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

David A. Braun, MD, PhD, provides clinical insights on factors that influence treatment decisions in the second line and beyond for patients with advanced clear cell RCC.

Focusing on the LITESPARK-003 and LITESPARK-024 trials, Laurence Albigès, MD, PhD, discusses novel doublet regimens under investigation in the first-line setting in advanced renal cell carcinoma.

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

The expert panel reacts to 55-month follow-up data from CheckMate 9ER assessing nivolumab plus cabozantinib in patients with newly diagnosed advanced RCC.

David A. Braun, MD, PhD, shares his takeaways from the network meta-analysis on lenvatinib plus pembrolizumab in advanced RCC, and Martin H. Voss, MD, discusses outcomes with cabozantinib following frontline lenvatinib plus pembrolizumab.

Chandler H. Park, MD, discusses the LEAP study investigating lenvatinib plus pembrolizumab in patients with renal cell carcinoma with brain metastasis.

Martin H. Voss, MD, gives an overview of the CLEAR study evaluating lenvatinib plus pembrolizumab in frontline advanced RCC and discusses recent subgroup analyses.

Laurence Albigès, MD, PhD, reviews recently presented data from CheckMate 67T, which is assessing subcutaneous vs intravenous nivolumab in patients with previously treated RCC.

The expert panel discusses the 8-year follow-up data from CheckMate 214 looking at nivolumab plus ipilimumab in first-line advanced RCC and provide clinical insights on treatment decisions.

A panel of medical oncologists who specialize in renal cell carcinoma (RCC) introduce themselves and discuss the first-line treatment landscape and risk stratification of clear cell RCC.

Benjamin Garmezy, MD, discusses in when to choose an IO/TKI regimen for the treatment of patients with ccRCC.

Benjamin Garmezy, MD, discusses the impact of frontline combination regimens on patient outcomes in patients with renal cell carcinoma.

Benjamin Garmezy, MD, discusses key considerations for the selection of frontline treatment regimens in clear cell renal cell carcinoma.

Benjamin Garmezy, MD, discusses the treatment of patients with cancer in the community care setting, highlighting the need to include those from this population in enrollment to clinical trials.

Kidney and renal pelvis cancers are one of the 10 most common new malignant diagnoses in both men and women in the United States, with an estimated 52,360 new cases in men and 29,440 new cases in women per year.

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, close their discussion with clinical pearls for community oncologists treating patients with advanced RCC.

Drs Barata and Garmezy give detailed thoughts on treating patients with advanced RCC who have received prior immune checkpoint inhibitors.

A comprehensive overview of the TIVO-3 trial, which compared tivozanib with sorafenib in patients with advanced renal cell carcinoma.

Experts on renal cell carcinoma discuss post-progression treatment options for RCC.

Pedro Barata, MD, MSc, and Benjamin Garmezy, MD, outline factors taken into consideration when selecting advanced RCC treatments.

Renal cell carcinoma experts discuss clinical trials, evaluating immunotherapies and tyrosine kinase inhibitors in the front line setting of advanced RCC.